Return to homepagePandemic Pact

APEIRON Biologics AG

  • Funded by Austrian Research Promotion Agency (FFG)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Austrian Research Promotion Agency (FFG)

  • Research Location

    Austria

  • Lead Research Institution

    APEIRON Biologics AG

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The drug candidate APN01 (rhACE2) is a synthetic enzyme with the potential to block the infection of cells by the coronavirus and thus counteract inflammatory reactions in the lungs. The door is locked for the virus, thus protecting organs. In a clinical study, the effectiveness is examined in sick people.